Short answer: no, not anymore. Sermorelin was FDA-approved once, decades ago, under a brand name most people have never heard of. That approval still exists on paper as a historical record, but the approved product itself is gone from the market. What is sold today under the name “sermorelin” is compounded — legal in most cases, but categorically not the same thing as FDA-approved. The difference between “legal” and “approved” is exactly where most of the confusion about this drug comes from. For what the compound actually does mechanistically, separate from its regulatory status, see what is sermorelin.
When was sermorelin FDA-approved, and why was it discontinued?
Sermorelin acetate was FDA-approved twice, both times under the brand name Geref, both times to the same manufacturer, EMD Serono. The first approval was in December 1990, for an injectable ampule formulation. The second came in September 1997, for higher-strength vials, and carried an orphan-drug designation [1]. Both approvals still exist in FDA’s records — but both products are now listed with a marketing status of Discontinued [1].
Here is the detail that actually matters, and it is a genuinely reassuring one, not a red flag: both discontinued Geref records carry FDA’s specific determination that the product was “not discontinued or withdrawn for safety or effectiveness reasons” [1]. In plain terms, Geref did not get pulled because it turned out to be dangerous or because it stopped working. It was discontinued for commercial reasons — the kind of business decision that ends a lot of older, lower-volume drug products. That determination is also the specific regulatory fact that keeps sermorelin acetate eligible to be used as an ingredient in compounded preparations today. A withdrawal for safety or efficacy reasons would generally have closed that door.
Is compounded sermorelin FDA-approved?
Once Geref was discontinued, no company continued to hold an FDA-approved, finished sermorelin product on the market. What exists instead is sermorelin acetate as a bulk compounding ingredient — raw powder, sold to compounding pharmacies and outsourcing facilities, which then prepare it into an injectable product themselves. Checking FDA’s current drug listing records directly confirms this is the entire current market. Every active sermorelin acetate listing found is categorized as bulk ingredient for prescription compounding, not as an approved finished drug product [2].
This distinction is the whole regulatory story in one sentence: FDA approval is a determination about a specific, finished, manufactured product. That means the exact formulation, the exact manufacturing process, and the exact dose — not a chemical in the abstract. When a pharmacy compounds sermorelin from bulk powder, that compounded product has never itself gone through FDA’s approval process, no matter how well-established the underlying chemical’s history is. That is true of every compounded drug, not something specific to sermorelin.
One detail worth being precise about: FDA does track certain bulk substances used in outsourcing-facility compounding under section 503B of the FD&C Act. It sorts nominated substances into evaluation categories. Checking FDA’s current 503B bulk drug substances list directly, sermorelin acetate appears in Category 1 — “Bulk Drug Substances Under Evaluation”. It is specifically flagged there as a substance that is a component of an FDA-approved drug (the historical Geref approval) [3]. “Under evaluation” is exactly what it sounds like: FDA has not finished a formal determination on it either way. It is not a form of approval.
What is sermorelin’s FDA status in 2026?
Unchanged by the 2026 peptide headlines. Under section 503A, a state-licensed pharmacy may compound from a bulk substance that is a component of an FDA-approved drug product, which is the route the historical Geref approval keeps open for sermorelin acetate [7]. FDA’s separate list of bulk substances that may present significant safety risks in compounding, known as Category 2, does not mention sermorelin at all as of the page updated April 22, 2026. That list does carry several peptides often sold beside it: ipamorelin acetate remains in Category 2 for 503B outsourcing facilities, and CJC-1295 and BPC-157 appear among substances whose nominations were withdrawn [5]. FDA’s July 2026 compounding advisory committee agenda did not include sermorelin [6]. The full picture, peptide by peptide, is in sermorelin’s legal status in 2026, and the rest of the class is compared in the guide to growth hormone peptides.
Is sermorelin legal?
Yes, when it comes through a licensed prescriber and a licensed compounding pharmacy or outsourcing facility; “legal” and “FDA-approved” are different claims, and no approved sermorelin product is on the market today [1]. The federal and state detail is in is sermorelin legal in 2026, and the lawful route to a prescription is in how to get a sermorelin prescription.
Is sermorelin a controlled substance?
No. Checking the DEA’s current federal controlled-substances list directly — the same alphabetical schedule that would list any substance regulated under the Controlled Substances Act — sermorelin does not appear on it [4]. That puts it in a different legal category than anabolic steroids, which are explicitly scheduled. See what is sermorelin, and is it a steroid for that distinction in full. Not being a scheduled controlled substance does not mean sermorelin is unregulated, though — it is still a prescription drug.
What does this mean when you are choosing a seller?
There is no approved finished product to point to. So the usual “is this brand FDA-approved” shortcut does not apply to sermorelin the way it would with a conventional prescription drug. That makes the questions worth asking different, not fewer. A legitimate compounded-sermorelin pathway should involve an actual prescriber evaluating you, not just a form that auto-approves everyone. It should also involve a pharmacy or outsourcing facility that is licensed and inspectable. Those two things — a real prescriber and a licensed, accountable pharmacy — are what stand in for “FDA-approved” in a compounded-drug world. See the telehealth prescribers listed here for sellers that actually run a prescriber-led intake, and what dose the trials actually used before taking a seller's dosing chart on faith.
The bottom line
Sermorelin was FDA-approved, under the name Geref, from 1990 until it was discontinued for commercial — not safety — reasons [1]. What is sold today is compounded from bulk sermorelin acetate. That is a legal and established pathway — but it is not, and cannot correctly be called, FDA approval [2]. FDA currently lists sermorelin acetate as a 503B bulk substance “under evaluation,” which is an open question, not a form of clearance [3]. And sermorelin is not a scheduled controlled substance under current federal law [4]. The single most useful thing to take away: legal and approved are not the same claim. Anyone selling you compounded sermorelin as “FDA-approved” is telling you something that is not true. For what the trials measured rather than what regulators say, see does sermorelin work.